Replimune Amends S-3 to Register 25.1M Share Resale by Baker Brothers as Going Concern and FDA Review Loom
REPL has more than doubled off its 52-week low of $1.5.
Summary
Replimune amended its shelf registration to allow Baker Brothers to resell up to 25.1 million shares, including 14.1 million underlying pre-funded warrants. The filing comes as the company faces a going concern warning and a pivotal FDA advisory committee meeting on July 30 for its melanoma therapy.
Key Events · Financing and Capital Events · REPL
-
Resale Registration for 25.1M Shares
Amendment No. 1 to the S-3 registers the resale of 25,103,489 shares by Baker Brothers entities, including 14,058,153 shares issuable upon exercise of pre-funded warrants. The shares represent 25.94% of outstanding common stock.
-
No Proceeds to Company
Replimune will not receive any proceeds from the resale of shares by the selling stockholders, though it may receive nominal proceeds from the exercise of pre-funded warrants.
-
Going Concern Risk Highlighted
The prospectus incorporates the going concern warning from the March 31, 2026 10-K, stating that existing cash will fund operations only into Q1 2027, less than one year from the filing date.
-
FDA Advisory Committee on July 30
The FDA has scheduled an advisory committee meeting on July 30, 2026 to review the resubmitted BLA for RP1 in advanced melanoma, with an action date of August 2, 2026. The outcome is binary for the company's future.
Analysis · REPL · Life Sciences
Replimune is registering the resale of 25.1 million shares held by Baker Brothers, a 25.9% stakeholder with a board seat. The original S-3 from May 2025 was never declared effective because of a government shutdown. This amendment updates the prospectus with the company's going concern warning, recent FDA complete response letters for its lead drug candidate, and the upcoming advisory committee meeting on July 30. While the company receives no proceeds from the resale, the registration enables a major investor to sell a large block at a critical time — just days before an FDA advisory panel and with cash runway only into Q1 2027. The overhang of a potential sale by a key insider could pressure the stock, especially given the binary regulatory outcome ahead.
At the time of this filing, REPL was trading at $9.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $814.5M. The 52-week trading range was $1.50 to $12.50. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.